In addition, data from the Phase 1b BEDIVERE trial were recently presented at the
About the Janssen GALAHAD Clinical Trial
GALAHAD is an ongoing Phase 2, open-label, single arm trial designed to evaluate the safety and efficacy of niraparib monotherapy (300mg daily) in men with metastatic castration-resistant prostate cancer (mCRPC) and DNA-repair anomalies progressing on/after taxane-based chemotherapy and androgen receptor targeted therapy. Patients are enrolled in the study based on their DNA-repair deficiency status.
About the Janssen BEDIVERE Clinical Trial
BEDIVERE is an ongoing Phase 1b, open-label, dose-selection study with dose expansion designed to evaluate the safety of niraparib in combination with AA-P in men with metastatic castration-resistant prostate cancer (mCRPC) who may or may not have had DNA-repair anomalies.
About ZEJULA® (Niraparib)
Niraparib is marketed in
Director, Investor Relations
+1.781.257.2505 or firstname.lastname@example.org
Forward Looking Statements:
To the extent that statements contained in this press release are not descriptions of historical facts regarding
Source: TESARO, Inc.